Sensei Biotherapeutics, Inc. Price & Performance (SNSE)

Sensei Biotherapeutics, Inc. has reported a significant 14.1% drop in short interest as of late February, now totaling 146,700 shares. This marks improved sentiment for the company, which is focused on immuno-oncology therapeutics. Institutional investors have also increased their stakes, with one firm raising its holdings by 355.8% in the third quarter.1

Vaxart has announced a 10% workforce reduction following a U.S. government halt on a vaccine trial. This move reflects broader challenges in the biotech sector, with several companies, including Eisai and Ryvu Therapeutics, also announcing layoffs as they adjust strategies to extend cash runways and focus on key programs.2

Several biotech companies, including Viracta Therapeutics and Turnstone Biologics, are undergoing major layoffs and restructuring efforts. Viracta is shutting down entirely, while Turnstone is halting its TIDAL-01 program. These decisions highlight ongoing financial pressures and a focus on prioritizing key assets or seeking strategic alternatives.2